Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress

NEXT STORY
Medical Device Packaging Market to reach USD 61.91 billion by 2027 – Report by Market Research Future (MRFR)
PREV STORY
Global Continuing Medical Education Markets 2021-2026: Oncology, Cardiology, Infectious Disease, Orthopedic, Gastroenterology, Pediatric, Primary Care
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer

Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in ...

author_avatar
NASDAQ Market News

G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights

Completed enrollment of Phase 2a small-cell lung cancer trial, with topline data expected in ...

author_avatar
NASDAQ Market News

PositiveID’s ExcitePCR Subsidiary to Hold Press Conference Announcing Lawrence Livermore National Report on its FireflyDX

DELRAY BEACH, Fla., Sept. 12, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation's (OTCQB:PSID) ExcitePCR subsidiary today ...

author_avatar
NASDAQ Market News